Keyword Connections

immunotherapy

Journals

51

1 Scientific reports

2 Communications biology

3 European journal of pharmacology

4 Life sciences

5 seminars in cancer biology

6 plos medicine

7 biomaterials

8 Data in brief

9 methods in molecular biology (clifton, nj)

10 international immunopharmacology

11 journal of drugs in dermatology : jdd

12 Journal of controlled release : official journal of the Controlled Release Society

13 Cells

14 Lancet (London, England)

15 modern pathology : an official journal of the united states and canadian academy of pathology, inc

16 Cancers

17 Frontiers in immunology

18 The Journal of antimicrobial chemotherapy

19 urologia

20 clinical epigenetics

21 European journal of cancer (Oxford, England : 1990)

22 Advances in therapy

23 journal of hepatology

24 digestive and liver disease : official journal of the italian society of gastroenterology and the italian association for the study of the liver

25 acta medica academica

26 JAMA network open

27 Frontiers in oncology

28 neuropsychology

29 cancer immunology, immunotherapy : cii

30 Vaccine

31 journal for immunotherapy of cancer

32 clinica chimica acta; international journal of clinical chemistry

33 bulletin du cancer

34 nursing history review : official journal of the american association for the history of nursing

35 Annals of oncology : official journal of the European Society for Medical Oncology

36 the oncologist

37 Future oncology (London, England)

38 european urology

39 Updates in surgery

40 journal of experimental & clinical cancer research : cr

41 aorta (stamford, conn)

42 journal of clinical tuberculosis and other mycobacterial diseases

43 revista espanola de patologia : publicacion oficial de la sociedad espanola de anatomia patologica y de la sociedad espanola de citologia

44 current protocols in pharmacology

45 expert review of clinical immunology

46 Current oncology reports

47 Cancer Discovery

48 melanoma management

49 clinical & translational immunology

50 asian pacific journal of allergy and immunology

51 Methods in molecular biology (Clifton, N.J.)

Research Groups

0

No Research Group Connected

Bibliographies

367

1 [An integral view of cancer (II). Fields of investigation and emerging biomarkers].

2 Targeting T cell metabolism in the tumor microenvironment: an anti-cancer therapeutic strategy.

3 Transgenic Tumor Models for Evaluating CAR T-Cell Immunotherapies.

4 Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).

5 A National Survey of Marijuana Use Among US Adults With Medical Conditions, 2016-2017.

6 The History of the FDA's Fight for Consumer Protection and Public Health, by US Food and Drug Administration.

7 Cyclic Multiplexed-Immunofluorescence (cmIF), a Highly Multiplexed Method for Single-Cell Analysis.

8 Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors.

9 SQ house dust mite sublingual immunotherapy for the treatment of adults with house dust mite-induced allergic rhinitis.

10 Beta-Blockers for Pyogenic Granuloma: A Systematic Review of Case Reports, Case Series, and Clinical Trials

11 Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting.

12 Survivor and patient advocate: an interview with T.J. Sharpe.

13 Potential use of edaravone to reduce specific side effects of chemo-, radio- and immuno-therapy of cancers.

14 Chronic Immune Activation in Systemic Lupus Erythematosus and the Autoimmune PTPN22 Trp Risk Allele Drive the Expansion of FOXP3 Regulatory T Cells and PD-1 Expression.

15 Therapeutic options for coeliac disease: What else beyond gluten-free diet?

16 Phase III, placebo-controlled, randomized, double-blind trial of tableted, therapeutic TB vaccine (V7) containing heat-killed administered daily for one month.

17 Bladder cancer genomics.

18 A new scfv-based recombinant immunotoxin against EPHA2-overexpressing breast cancer cells; High in vitro anti-cancer potency.

19 Prognostic and predictive value of cell cycle progression (CCP) score in ductal carcinoma in situ of the breast.

20 Proteomic profiling of extracellular vesicles allows for human breast cancer subtyping.

21 Characteristics and outcome of AKT1 E17K-mutant breast cancer defined through AACR GENIE, a clinicogenomic registry.

22 Overcoming immunotherapeutic resistance by targeting the cancer inflammation cycle.

23 Heat Shock Proteins: Agents of Cancer Development and Therapeutic Targets in Anti-Cancer Therapy.

24 Remodeling tumor immune microenvironment via targeted blockade of PI3K-γ and CSF-1/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy.

25 Association of Steroids use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.

26 Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial.

27 Advances in Targeting the Innate and Adaptive Immune Systems to Cure Chronic Hepatitis B Virus Infection.

28 [Current advances in immunotherapy in ovarian cancer].

29 Cancer bio-immunotherapy XVI annual NIBIT-(Italian Network for Tumor Biotherapy) meeting, October 11-13 2018, Milan, Italy.

30 NFE2L2/KEAP1 mutations correlate with higher TMB value/PD-L1 expression and potentiate improved clinical outcome with immunotherapy.

31 Primary Sarcoma of Descending Aorta.

32 Combination therapy with liposomal doxorubicin and liposomal vaccine containing E75, an HER-2/neu-derived peptide, reduces myeloid-derived suppressor cells and improved tumor therapy.

33 Tumor-Derived Extracellular Vesicles Impair CD171-Specific CD4 CAR T Cell Efficacy.

34 Data analysis of PD-1 antibody in the treatment of melanoma patients.

35 Epigenetic prediction of complex traits and mortality in a cohort of individuals with oropharyngeal cancer.

36 Immune-related pneumonitis with nivolumab and ipilimumab during the coronavirus disease 2019 (COVID-19) pandemic.

37 Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis.

38 Application of Anti-Inflammatory Agents in Prostate Cancer

39 Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity

40 immunotherapy of invasive fungal infection in hematopoietic stem cell transplant recipients

41 editorial: radiation and the immune system: current knowledge and future perspectives

42 neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases

43 use of anti-cd20 therapy in follicular and marginal zone lymphoma: a review of the literature

44 regulation of cell death in cancer – possible implications for immunotherapy

45 tailoring dna vaccines: designing strategies against her2 positive cancers

46 fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations

47 ror1 and ror2 in human malignancies: potentials for targeted therapy

48 novel immunotherapeutic approaches for head and neck squamous cell carcinoma

49 selection of tumor-specific cytotoxic t lymphocytes in acute myeloid leukemia patients through the identification of t-cells capable to establish stable interactions with the leukemic cells: “doublet technology”

50 in vivo murine-matured human cd3+ cells as a preclinical model for t cell-based immunotherapies

51 efficacy and toxicity of immune -checkpoint inhibitors in patients with preexisting autoimmune disorders

52 inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for cancer: an overview of rationale, preclinical evidence, and initial clinical data

53 editorial: update on the treatment of metastatic non-small cell lung cancer (nsclc) in new era of personalised medicine

54 immunotherapy plus cryotherapy: potential augmented abscopal effect for advanced cancers

55 immunotherapeutic advancements for glioblastoma

56 botulinum neurotoxins and botulism: a novel therapeutic approach

57 influence of histone deacetylase inhibitors and dna-methyltransferase inhibitors on the nk cell-mediated lysis of pediatric b-lineage leukemia.

58 natural killer cell-based immunotherapy in gynecologic malignancy: a review

59 molecular insights for optimizing t cell receptor specificity against cancer

60 natural killer cells for immunotherapy – advantages of cell lines over blood nk cells

61 γδ t cells and tumor microenvironment: from immunosurveillance to tumor evasion

62 natural killer cell based therapies targeting cancer: possible strategies to gain and sustain anti-tumor activity

63 the response of cd1d-restricted invariant nkt cells to microbial pathogens and their products

64 chronic granulomatous reaction in patients receiving vaccine immunotherapy for metastatic melanoma

65 evidence for oncolytic virotherapy: where have we got to and where are we going?

66 exploiting synergy: immune-based combinations in the treatment of prostate cancer

67 phosphatidylserine-liposomes promote tolerogenic features on dendritic cells in human type 1 diabetes by apoptotic mimicry

68 Title not found

69 epcam immunotherapy versus specific targeted delivery of drugs

70 emerging insights into barriers to effective brain tumor therapeutics

71 identifying individual t cell receptors of optimal avidity for tumor antigens

72 chemotherapy in advanced non-small cell lung cancer: present and future

73 rush specific oral tolerance induction in school-age children with severe egg allergy: one year follow up

74 spatial, temporal and functional aspects of macrophage during ‘the good, the bad and the ugly’ phases of inflammation

75 anti-pd-1 and anti-ctla-4 therapies in cancer: mechanisms of action, efficacy, and limitations

76 influence of irradiated peripheral blood mononuclear cells on both ex vivo proliferation of human natural killer cells and change in cellular property

77 exploring synergy in combinations of tumor-derived vaccines that harbor 4-1bbl, ox40l, and gm-csf

78 aberrant glycosylation of anchor-optimized muc1 peptides can enhance antigen binding affinity and reverse tolerance to cytotoxic t lymphocytes

79 targeting nk cells for anti-cancer immunotherapy: clinical and pre-clinical approaches

80 a case of poorly differentiated large-cell neuroendocrine carcinoma of the cecum: a rare malignancy, with review of the literature

81 molecular engineering of therapeutic cytokines

82 improvement of peptide-based tumor immunotherapy using ph-sensitive fusogenic polymer-modified liposomes

83 dysregulated expression of glycolipids in tumor cells: from negative modulator of anti-tumor immunity to promising targets for developing therapeutic agents

84 harnessing mechanistic knowledge on beneficial versus deleterious ifn-i effects to design innovative immunotherapies targeting cytokine activity to specific cell types

85 tumor necrosis factor-308 polymorphism with the risk and prognosis of non-hodgkin lymphomas: a meta-analysis study

86 evolving role of immunotherapy in head-and-neck cancers: a systemic review

87 differential sensitivity of regulatory and effector t cells to cell death: a prerequisite for transplant tolerance

88 corrigendum: glycobiology of neuroblastoma: impact on tumor behavior, prognosis, and therapeutic strategies

89 radiation as an immunological adjuvant: current evidence on dose and fractionation

90 new methods for predicting the sensitivity of renal cancer to immunotherapy on the basis of analysis of molecular genetic characteristics of a tumor

91 immunotherapy for metastatic kidney cancer: its role at the present stage and prospects for clinical application

92 hepatocellular carcinoma: past and future of molecular target therapy

93 potential therapeutic strategies for non - muscle invasive bladder cancer based on association of intravesical immunotherapy with p-mapa and systemic administration of cisplatin and doxorubicin

94 regulation of pd-l1: emerging routes for targeting tumor immune evasion

95 immune checkpoint targets for host-directed therapy to prevent and treat leishmaniasis

96 cardiotoxic effects of the novel approved anti-erbb2 agents and reverse cardioprotective effects of ranolazine

97 bioinformatic description of immunotherapy targets for pediatric t-cell leukemia and the impact of normal gene sets used for comparison

98 commentary: heart failure with preserved ejection fraction induces beiging in adipose tissue

99 Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality

100 Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors

101 Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy